FDA Welcomes Sotagliflozin Data for Heart Failure in Diabetes FDA Welcomes Sotagliflozin Data for Heart Failure in Diabetes

The FDA says data from two pivotal trials can be used to help support a new drug application for the dual SGLT1/2 inhibitor, according to a statement by Lexicon Pharmaceuticals.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news